BMS 911543

Drug Profile

BMS 911543

Alternative Names: BMS-911543

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myelofibrosis

Most Recent Events

  • 09 Oct 2017 Discontinued - Phase-I/II for Myelofibrosis (Second-line therapy or greater) in Australia and USA (PO) (Drug not listed on Bristol-Myers Squibb pipeline, October 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2015 Bristol-Myers Squibb completes a phase I/II trial in Myelofibrosis (Second-line therapy or greater) in USA and Australia (PO) (NCT01236352)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top